WHAT IS CLAIMED IS:

1. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:



[I]

(wherein the cyclic amino group is represented by the following formula [II]:



[II]

in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C_{1-5}alkylene or C_{1-4}alkylene-O-C_{1-4}alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by $-(CR^1R^2)_m-(CHR^3)_n-X$, R^4 and R^5 independently on the same or different carbon atoms of the cyclic amine;

X is cyano or hydroxy;

Y is N or CH;

R^1 is hydrogen, hydroxy, C_{1-5}alkyl, C_{1-5}alkoxy-C_{1-5}alkyl or hydroxy-C_{1-5}alkyl;

R^2 is hydrogen or C_{1-5}alkyl;

R^3 is hydrogen, cyano, C_{1-5}alkyl, C_{1-5}alkoxy-C_{1-5}alkyl or hydroxy-C_{1-5}alkyl;

m is an integer selected from 0, 1, 2, 3, 4 and 5;

n is 0 or 1;

R^4 is hydrogen, hydroxy, hydroxy-C_{1-5}alkyl, cyano, cyano-C_{1-5}alkyl or C_{1-5}alkyl;

R^5 is hydrogen or C_{1-5}alkyl;

R^6 is hydrogen, C_{1-5}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-5}alkyl, hydroxy, C_{1-5}alkoxy, C_{3-8}cycloalkyloxy or $-N(R^8)R^9$;

R^7 is hydrogen, halogen, C_{1-5}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-5}alkyl, hydroxy, C_{1-}

$_5$alkoxy, C_{3-8}cycloalkyloxy, -N(R^{10})R^{11}, -CO_2R^{12}, cyano, nitro, C_{1-5}alkylthio, trifluoromethyl or trifluoromethoxy;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C_{1-5}alkyl, C_{3-8}cycloalkyl, C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-5}alkoxy, C_{1-5}alkylthio, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and -N(R^{13})R^{14};

R^8 and R^9 are the same or different, and independently are hydrogen or C_{1-5}alkyl;

R^{10} and R^{11} are the same or different, and independently are hydrogen or C_{1-5}alkyl;

R^{12} is hydrogen or C_{1-5}alkyl;

R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-5}alkyl)

, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

2. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [III]:



[III]

(wherein X, m, n, the cyclic amino group, R^1, R^2, R^3, R^4, R^5, R^6, R^7 and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

3. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R^1, R^2, R^4 and R^5 are hydrogen; R^6 is C_1-

$_5$alkyl; R^7 is hydrogen or C_{1-5}alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3}alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

4. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R^1, R^2, R^4 and R^5 are hydrogen; R^6 is C_{1-5}alkyl; R^7 is hydrogen or C_{1-5}alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3}alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

5. The thienopyridine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [IV]:



[IV]

(wherein X, m, n, the cyclic amino group, R^1, R^2, R^3, R^4, R^5, R^6, R^7 and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

6. The thienopyridine derivative substituted with the cyclic amino group according to claim 5 represented by formula [IV], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R^1, R^2, R^4 and R^5 are hydrogen; R^6 is C_{1-5}alkyl; R^7 is hydrogen or C_{1-5}alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3}alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

7. The thienopyridine derivative substituted with the cyclic amino group according to claim 5 represented by formula [IV], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R^1, R^2, R^4 and R^5 are hydrogen; R^6 is C_{1-5}alkyl; R^7 is hydrogen or C_{1-5}alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{13})R^{14}$ (wherein R^{13} and R^{14} are the same or different, and independently are hydrogen or C_{1-3}alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

8. An antagonist for CRF receptors, comprising a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 7, as an active ingredient.

9. Use of a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 7, for the manufacture of an antagonist for CRF receptors.